DKFZ spin-off Epignostix raises €4.3m seed round to commercialize diagnostic tumor classifier
Precise cancer classification of subtypes that are otherwise difficult or impossible to distinguish
Heidelberg Epignostix GmbH, a deeptech start-up committed to precision cancer diagnostics announces €4.3M in seed funding. This investment will enable Heidelberg Epignostix to make a substantial leap forward in driving market development for its flagship indication for brain tumor classification.
CARMA FUND I Capital GmbH & Co KG led the round with participation from High-Tech Gründerfonds, LBBW Venture Capital GmbH and Start-up BW Seed Fonds. Heidelberg Epignostix’ technology is underpinned by more than ten years of intensive research originally at the Hopp Children’s Cancer Center Heidelberg (KiTZ), the German Cancer Research Center (DKFZ), Heidelberg University Hospital (UKHD) and Heidelberg University. Combining epigenetics with artificial intelligence-powered bioinformatics, their software algorithms enable precise cancer classification of subtypes that are otherwise difficult or impossible to distinguish. The technology is based on DNA methylation which is a pattern of chemical tags on tumor DNA functioning as genomic fingerprints. The algorithm has been applied to more than 150,000 patient samples to date.
The company is addressing brain tumor classification due to the high need for improved diagnostic accuracy. Methylation-based tumor classification is now recommended by WHO guidelines as a precise classification tool which enables enhanced clinical care for cancer patients.
“CARMA FUND I Capital is excited to support this highly promising approach in precision cancer diagnostics” said Martin Raditsch, managing partner of CARMA. Katharina Severin, Investment Manager at High-Tech Gründerfonds adds: “We very much look forward to working with the outstanding Epignostix team to create a transformative portfolio for cancer diagnostics in brain tumors and beyond.”
“Heidelberg Epignostix is absolutely thrilled to have secured financial backing from a group who have profound expertise in healthcare and the oncology market,” said David Jones from KiTZ and DKFZ, co-founder and general manager at Heidelberg Epignostix. “We have a very robust technology, and we expect to bring the Heidelberg Brain Tumor Classifier as an approved diagnostic test to the market in 2025.” Felix Sahm, co-founder and Head of Molecular Neuropathology at the Heidelberg University Hospital adds: “We are focusing on brain tumors first, where a sizeable patient population and high relevance in childhood cancer have already led to rapid adoption but will expand into other tumor indications quickly.”
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
See the theme worlds for related content
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
Topic world Diagnostics
Diagnostics is at the heart of modern medicine and forms a crucial interface between research and patient care in the biotech and pharmaceutical industries. It not only enables early detection and monitoring of disease, but also plays a central role in individualized medicine by enabling targeted therapies based on an individual's genetic and molecular signature.
